Do analysts rate NUWE or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, NUWE or PFSA?

Nuwellis has higher revenue and earnings than Profusa. Nuwellis is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.27M 0.05 -$17.52M -$64.02 N/A Profusa $100K 11.28 -$35.82M -$169.72 N/A

Is NUWE or PFSA more profitable?

Profusa has a net margin of 0.00% compared to Nuwellis' net margin of -214.90%. Profusa's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -214.90% -32,351.83% -249.08% Profusa N/A N/A -1,348.07%

Does the media favor NUWE or PFSA?

In the previous week, Nuwellis had 3 more articles in the media than Profusa. MarketBeat recorded 6 mentions for Nuwellis and 3 mentions for Profusa. Profusa's average media sentiment score of 0.66 beat Nuwellis' score of 0.30 indicating that Profusa is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuwellis 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Profusa 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NUWE or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is NUWE or LYRA more profitable?

Nuwellis has a net margin of -214.90% compared to Lyra Therapeutics' net margin of -5,491.17%. Lyra Therapeutics' return on equity of -1,010.91% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -214.90% -32,351.83% -249.08% Lyra Therapeutics -5,491.17% -1,010.91% -58.92%

Do analysts prefer NUWE or SSKN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Strata Skin Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NUWE or SSKN more profitable?

Strata Skin Sciences has a net margin of -35.64% compared to Nuwellis' net margin of -214.90%. Strata Skin Sciences' return on equity of -476.73% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -214.90% -32,351.83% -249.08% Strata Skin Sciences -35.64% -476.73% -33.49%

Does the media prefer NUWE or SSKN?

In the previous week, Nuwellis had 4 more articles in the media than Strata Skin Sciences. MarketBeat recorded 6 mentions for Nuwellis and 2 mentions for Strata Skin Sciences. Nuwellis' average media sentiment score of 0.30 beat Strata Skin Sciences' score of 0.00 indicating that Nuwellis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuwellis 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Strata Skin Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DYNT or NUWE?

Given Dynatronics' higher possible upside, analysts plainly believe Dynatronics is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, DYNT or NUWE?

Dynatronics has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dynatronics $33.60M 0.00 -$2.70M -$1.35 N/A Nuwellis $8.27M 0.05 -$17.52M -$64.02 N/A

Is DYNT or NUWE more profitable?

Dynatronics has a net margin of -8.35% compared to Nuwellis' net margin of -214.90%. Dynatronics' return on equity of -41.81% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Dynatronics -8.35% -41.81% -9.56% Nuwellis -214.90% -32,351.83% -249.08%

Do analysts prefer NUWE or BIOL?

Given BIOLASE's higher possible upside, analysts clearly believe BIOLASE is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, NUWE or BIOL?

Nuwellis has higher earnings, but lower revenue than BIOLASE. Nuwellis is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.27M 0.05 -$17.52M -$64.02 N/A BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A

Is NUWE or BIOL more profitable?

BIOLASE has a net margin of -41.65% compared to Nuwellis' net margin of -214.90%. BIOLASE's return on equity of -1,782.73% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -214.90% -32,351.83% -249.08% BIOLASE -41.65% -1,782.73% -55.31%

Nuwellis (NUWE) Competitors

$0.14 0.00 (-0.70%)

As of 11:21 AM Eastern

Compare

NUWE vs. PFSA, LYRA, SSKN, DYNT, and BIOL

Should you buy Nuwellis stock or one of its competitors? MarketBeat compares Nuwellis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuwellis include Profusa (PFSA), Lyra Therapeutics (LYRA), Strata Skin Sciences (SSKN), Dynatronics (DYNT), and BIOLASE (BIOL). These companies are all part of the "medical equipment" industry.

How does Nuwellis compare to Profusa?

Nuwellis (NASDAQ:NUWE) and Profusa (NASDAQ:PFSA) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuwellis has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Profusa has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Nuwellis has higher revenue and earnings than Profusa. Nuwellis is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.05	-$17.52M	-$64.02	N/A
Profusa	$100K	11.28	-$35.82M	-$169.72	N/A

Profusa has a net margin of 0.00% compared to Nuwellis' net margin of -214.90%. Profusa's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Profusa	N/A	N/A	-1,348.07%

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 0.8% of Profusa shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Nuwellis had 3 more articles in the media than Profusa. MarketBeat recorded 6 mentions for Nuwellis and 3 mentions for Profusa. Profusa's average media sentiment score of 0.66 beat Nuwellis' score of 0.30 indicating that Profusa is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuwellis	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Profusa beats Nuwellis on 7 of the 13 factors compared between the two stocks.

How does Nuwellis compare to Lyra Therapeutics?

Nuwellis (NASDAQ:NUWE) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Nuwellis has a net margin of -214.90% compared to Lyra Therapeutics' net margin of -5,491.17%. Lyra Therapeutics' return on equity of -1,010.91% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

In the previous week, Nuwellis had 6 more articles in the media than Lyra Therapeutics. MarketBeat recorded 6 mentions for Nuwellis and 0 mentions for Lyra Therapeutics. Nuwellis' average media sentiment score of 0.30 beat Lyra Therapeutics' score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Overall Sentiment
Nuwellis	Neutral
Lyra Therapeutics	Neutral

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 1.6% of Nuwellis shares are held by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Nuwellis has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Nuwellis has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.05	-$17.52M	-$64.02	N/A
Lyra Therapeutics	$600K	1.63	-$93.43M	-$19.15	N/A

Summary

Lyra Therapeutics beats Nuwellis on 8 of the 14 factors compared between the two stocks.

How does Nuwellis compare to Strata Skin Sciences?

Nuwellis (NASDAQ:NUWE) and Strata Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Strata Skin Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Strata Skin Sciences has a net margin of -35.64% compared to Nuwellis' net margin of -214.90%. Strata Skin Sciences' return on equity of -476.73% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Strata Skin Sciences	-35.64%	-476.73%	-33.49%

In the previous week, Nuwellis had 4 more articles in the media than Strata Skin Sciences. MarketBeat recorded 6 mentions for Nuwellis and 2 mentions for Strata Skin Sciences. Nuwellis' average media sentiment score of 0.30 beat Strata Skin Sciences' score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuwellis	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Strata Skin Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Strata Skin Sciences has higher revenue and earnings than Nuwellis. Strata Skin Sciences is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.05	-$17.52M	-$64.02	N/A
Strata Skin Sciences	$30.98M	0.02	-$10.09M	-$1.41	N/A

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 32.4% of Strata Skin Sciences shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by insiders. Comparatively, 40.9% of Strata Skin Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nuwellis has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Strata Skin Sciences has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Summary

Strata Skin Sciences beats Nuwellis on 8 of the 13 factors compared between the two stocks.

How does Nuwellis compare to Dynatronics?

Dynatronics (NASDAQ:DYNT) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Given Dynatronics' higher possible upside, analysts plainly believe Dynatronics is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dynatronics has a net margin of -8.35% compared to Nuwellis' net margin of -214.90%. Dynatronics' return on equity of -41.81% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dynatronics	-8.35%	-41.81%	-9.56%
Nuwellis	-214.90%	-32,351.83%	-249.08%

In the previous week, Nuwellis had 6 more articles in the media than Dynatronics. MarketBeat recorded 6 mentions for Nuwellis and 0 mentions for Dynatronics. Nuwellis' average media sentiment score of 0.30 beat Dynatronics' score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Overall Sentiment
Dynatronics	Neutral
Nuwellis	Neutral

Dynatronics has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A
Nuwellis	$8.27M	0.05	-$17.52M	-$64.02	N/A

4.2% of Dynatronics shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 2.9% of Dynatronics shares are held by company insiders. Comparatively, 1.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Dynatronics has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Summary

Dynatronics beats Nuwellis on 10 of the 14 factors compared between the two stocks.

How does Nuwellis compare to BIOLASE?

Nuwellis (NASDAQ:NUWE) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Nuwellis has higher earnings, but lower revenue than BIOLASE. Nuwellis is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.05	-$17.52M	-$64.02	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

Given BIOLASE's higher possible upside, analysts clearly believe BIOLASE is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nuwellis has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Comparatively, 0.3% of BIOLASE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BIOLASE has a net margin of -41.65% compared to Nuwellis' net margin of -214.90%. BIOLASE's return on equity of -1,782.73% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
BIOLASE	-41.65%	-1,782.73%	-55.31%

In the previous week, Nuwellis had 6 more articles in the media than BIOLASE. MarketBeat recorded 6 mentions for Nuwellis and 0 mentions for BIOLASE. Nuwellis' average media sentiment score of 0.30 beat BIOLASE's score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Overall Sentiment
Nuwellis	Neutral
BIOLASE	Neutral

Summary

BIOLASE beats Nuwellis on 9 of the 14 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUWE vs. The Competition

Export

Metric	Nuwellis	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$381K	$7.06B	$6.50B	$12.32B
Dividend Yield	N/A	1.21%	2.67%	5.66%
P/E Ratio	0.00	48.29	24.00	24.65
Price / Sales	0.05	85.57	543.88	171.03
Price / Cash	N/A	25.59	27.48	37.92
Price / Book	0.09	6.90	10.73	6.84
Net Income	-$17.52M	$159.20M	$3.56B	$337.45M
7 Day Performance	-2.07%	-0.46%	1.34%	2.48%
1 Month Performance	-85.73%	5.51%	2.25%	4.36%
1 Year Performance	-98.79%	2.40%	26.20%	32.45%

Nuwellis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUWE Nuwellis	0.367 of 5 stars	$0.14 -0.7%	N/A	-98.8%	$381K	$8.27M	N/A	70	Gap Up
PFSA Profusa	0.2428 of 5 stars	$0.25 -9.7%	N/A	N/A	$1.28M	$100K	N/A	2	Gap Down
LYRA Lyra Therapeutics	0.2084 of 5 stars	$0.60 -25.0%	N/A	-95.1%	$1.07M	$600K	N/A	50	Gap Down
SSKN Strata Skin Sciences	0.107 of 5 stars	$0.13 +8.3%	N/A	-94.6%	$771K	$30.98M	N/A	120	News Coverage
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUWE) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuwellis (NUWE) Competitors

NUWE vs. PFSA, LYRA, SSKN, DYNT, and BIOL

How does Nuwellis compare to Profusa?

Summary

How does Nuwellis compare to Lyra Therapeutics?

Summary

How does Nuwellis compare to Strata Skin Sciences?

Summary

How does Nuwellis compare to Dynatronics?

Summary

How does Nuwellis compare to BIOLASE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuwellis (NUWE) Competitors

NUWE vs. PFSA, LYRA, SSKN, DYNT, and BIOL

How does Nuwellis compare to Profusa?

Do analysts rate NUWE or PFSA?

Which has more volatility and risk, NUWE or PFSA?

Which has stronger earnings & valuation, NUWE or PFSA?

Is NUWE or PFSA more profitable?

Do institutionals and insiders hold more shares of NUWE or PFSA?

Does the media favor NUWE or PFSA?

Summary

How does Nuwellis compare to Lyra Therapeutics?

Is NUWE or LYRA more profitable?

Does the media refer more to NUWE or LYRA?

Do insiders and institutionals hold more shares of NUWE or LYRA?

Do analysts recommend NUWE or LYRA?

Which has more risk and volatility, NUWE or LYRA?

Which has higher earnings & valuation, NUWE or LYRA?

Summary

How does Nuwellis compare to Strata Skin Sciences?

Do analysts prefer NUWE or SSKN?

Is NUWE or SSKN more profitable?

Does the media prefer NUWE or SSKN?

Which has preferable valuation and earnings, NUWE or SSKN?

Do institutionals and insiders have more ownership in NUWE or SSKN?

Which has more risk & volatility, NUWE or SSKN?

Summary

How does Nuwellis compare to Dynatronics?

Do analysts prefer DYNT or NUWE?

Is DYNT or NUWE more profitable?

Does the media prefer DYNT or NUWE?

Which has stronger earnings and valuation, DYNT or NUWE?

Do insiders and institutionals hold more shares of DYNT or NUWE?

Which has more risk & volatility, DYNT or NUWE?

Summary

How does Nuwellis compare to BIOLASE?

Which has preferable earnings and valuation, NUWE or BIOL?

Do analysts prefer NUWE or BIOL?

Which has more risk and volatility, NUWE or BIOL?

Do insiders & institutionals have more ownership in NUWE or BIOL?

Is NUWE or BIOL more profitable?

Does the media refer more to NUWE or BIOL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools